查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930045

自閉症譜系障礙（ASD）治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2025-2034）

Autism Spectrum Disorder Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 162 Pages | 商品交期: 請詢問到貨日

價格

自閉症譜系障礙（ASD）治療市場成長驅動因素

全球自閉症譜系障礙（ASD）治療市場在2025年達到 22.1億美元，並預計在預測期內穩定成長。報告顯示，該市場預計將從2026年的23.3億美元成長到2034年的40.6億美元，2026年至2034年的年複合成長率（CAGR）為 6.51%。該成長趨勢得益於 ASD 盛行率的上升、公眾意識的提高以及政府主導的目的是早期診斷和增加治療機會的各項措施。

自閉症譜系障礙（ASD）是一組神經發育障礙，其特徵是社交溝通障礙、興趣狹窄和重複性行為。這些障礙包括自閉症、亞斯伯格症和廣泛性發展障礙（PDD）。全球 ASD 診斷率的上升顯著增加了對目的是控制行為症狀和相關合併症的藥物治療的需求。

市場動態

市場驅動因素

自閉症譜系障礙（ASD）治療市場的主要驅動因素之一是政府主導的目的是提高公眾對 ASD 的認識和早期診斷的舉措日益增多。多個地區的政府投資公共教育計畫、資助自閉症專項基金會並實施全面的醫療保健政策。這些努力促進了症狀的早期發現，並直接增加了對治療介入的需求。

例如，2025年5月，巴西體育部在國際殘疾人權利大會上宣布了一項以自閉症為重點的體育融合計劃。此類計畫凸顯了機構對自閉症譜系障礙（ASD）患者的支持力度不斷加大，對治療的接受度和市場成長產生了積極影響。

市場限制因子

儘管人們對自閉症的認識不斷提高，但由於補充和替代療法（CAM）的普及，市場仍面臨一些限制因素。螯合療法、高壓氧療法、針灸和飲食療法等治療方法越來越受到照護者的青睞，限制了傳統藥物療法的應用。根據美國兒科學會2023年3月發布的報告，近95%的自閉症譜系障礙兒童至少嘗試過一種替代療法。

市場機會

由於FDA核准的藥物供應有限，自閉症譜系障礙治療市場蘊藏著巨大的機會。目前，僅有利於培酮和阿立哌唑獲準用於治療自閉症譜系障礙（ASD）的藥物，但這些藥物主要針對易怒和攻擊性行為，而非ASD的核心症狀。這種未被滿足的需求促使製藥公司將重點放在針對社交溝通障礙和重複行為的創新療法上。

市場挑戰

自閉症治療的高成本仍然是一個主要挑戰。長期治療、專家諮詢和品牌藥物給家庭帶來了沉重的經濟負擔，尤其是在中低收入國家。即使是已獲批藥物的仿製藥價格仍然昂貴，限制了藥物的可及性，並減緩了市場滲透。

自閉症譜系障礙（ASD）治療市場趨勢

影響市場發展的關鍵趨勢包括ASD治療臨床研發管線的擴展與創新。多家公司投資新的藥理作用機制，包括神經調節療法、酵素替代療法、催產素療法和谷氨酸能藥物。越來越多的藥物被超適應症使用，進一步凸顯了針對自閉症譜系障礙（ASD）核心症狀的核准療法的迫切性。

市場區隔分析

依藥物類型

依藥物類型劃分，市場包括抗精神病藥、選擇性血清素再攝取抑制劑（SSRI）/抗憂鬱藥、興奮劑和助眠藥。興奮劑將在2026年佔據市場主導地位，市場佔有率達28.65%。這主要是因為它們在控制ASD患者的注意力不足過動症（ADHD）相關症狀（例如過動和注意力不集中）方面具有療效。

依疾病類型

根據疾病分類，自閉症譜系障礙（ASD）將在2026年佔據最大的市場佔有率，達到55.41%。這主要是由於其高盛行率以及政府支持的干預計畫數量的增加。

依年齡層劃分

預計兒科市場成長最快，主要得益於早期診斷和家長意識的提高。同時，成人市場在2026年將佔總市場的71.3%，反映了成人持續的治療需求。

依通路劃分

醫院藥局在2026年將佔據市場主導地位，市場佔有率達39.57%，主要得益於專科處方、保險覆蓋及管制藥品分發等因素。

區域洞察

預計北美地區在2025年將引領全球自閉症譜系障礙（ASD）治療市場，創造12.8億美元的收入，佔市場佔有率的58.1%。這一主導地位歸功於較高的認知度、完善的償付體系和不斷提高的診斷率。預計到2026年，光是美國市場規模就將達到12.6億美元。

歐洲佔第二大市場佔有率，這得益於篩檢計畫的改進和研究措施的推進。同時，亞太地區預計將以最高的年複合成長率成長，這主要得益於公眾意識的提高、醫療基礎設施的擴張以及日本、中國和印度等國家研究活動的增加。

這份 "自閉症譜系障礙（ASD）治療市場" 報告對全球產業進行了全面系統的分析，重點在於定性和定量分析。報告內容包括2025年基準年市場規模和價值的詳細評估、2026年的預測值、直至2034年的長期預測以及預測期內的相關年複合成長率。

本報告深入分析了市場動態，包括影響市場擴張的關鍵驅動因素、限制因素、機會和挑戰。本報告深入分析了政府措施、宣傳活動、定價挑戰以及輔助和替代療法對傳統自閉症譜系障礙（ASD）藥物應用的影響。

本報告的大部分篇幅用於細分市場分析，涵蓋了依藥物類型、疾病類型、年齡層和通路劃分的市場。每個細分市場都從市場佔有率、成長潛力和潛在需求驅動因素等方面進行了分析。基於已發表的資料，本報告還重點介紹了特定細分市場的主導地位，例如興奮劑、自閉症譜系障礙（ASD）、成人患者和醫院藥房。

此外，本報告還提供了詳細的區域展望，分析了北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的市場表現。區域分析包括市場規模、成長驅動因素、醫療保健基礎設施、償付方案以及適用的國家/地區特定資訊。

此外，本報告還提供了全面的競爭格局分析，包括對主要市場參與者的概況介紹，以及對研發活動、臨床管線拓展、合作關係和產品開發等策略措施的評估。報告還涵蓋了近期發展動態，以幫助全面了解競爭格局。

總而言之，本報告為自閉症譜系障礙（ASD）治療市場的當前趨勢、未來成長前景和結構動態提供了切實可行的見解，可作為利害關係人的策略資源。

FDA 核准的治療藥物供應有限，凸顯了巨大的未滿足需求，促使製藥公司加強研發和創新力度。同時，不斷上漲的治療成本和對替代療法的日益依賴，持續對市場滲透構成挑戰，尤其是在成本敏感地區。

依地區劃分，北美憑藉其先進的醫療保健基礎設施和有利的償付政策，保持著領先地位；而亞太地區則憑藉日益增強的健康意識和不斷擴大的研究活動，已成為一個高成長地區。

整體而言，市場前景依然樂觀。藥物研發的創新、支持性的政策框架以及全球對自閉症護理日益成長的關注，預計將塑造自閉症譜系障礙（ASD）治療行業到2034年的未來發展軌跡。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 關鍵考察

  • 主要國家自閉症盛行率（2025年）
  • 主要產業趨勢（併購、收購、合作等）
  • 主要國家的監管框架
  • 主要國家/地區自閉症譜系障礙（ASD）治療的全球償付和經濟負擔
  • 主要公司在研產品線分析

第5章 全球自閉症譜系障礙（ASD）治療藥物市場分析、洞察與預測（2021-2034）

  • 依藥物類型劃分的市場分析、洞察與預測
    • 抗精神病藥
    • 選擇性血清素再攝取抑制劑/抗憂鬱藥
    • 興奮劑
    • 安眠藥
    • 其他
  • 依疾病劃分的市場分析、洞察與預測
    • 自閉症
    • 亞斯伯格症症候群
    • 廣泛性發展障礙（PDD）
    • 其他
  • 市場分析、洞察與預測 - 依年齡層劃分
    • 成人
    • 兒科
  • 市場分析、洞察與預測 - 依通路劃分
    • 醫院藥房
    • 藥局及零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美自閉症譜系障礙（ASD）治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 美國
    • 加拿大

第7章 歐洲自閉症譜系障礙（ASD）治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區自閉症譜系障礙（ASD）治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞亞洲
    • 亞太其他地區

第9章 拉丁美洲自閉症譜系障礙（ASD）治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲自閉症譜系障礙（ASD）治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • GCC
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • Curemark, LLC
  • Yamo Pharmaceuticals
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Otsuka Holdings Co. Ltd.
  • Johnson &Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
Product Code: FBI101207

Growth Factors of autism spectrum disorder (ASD) therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market was valued at USD 2.21 billion in 2025 and is expected to witness steady expansion over the forecast period. According to the report, the market is projected to grow from USD 2.33 billion in 2026 to USD 4.06 billion by 2034, registering a CAGR of 6.51% during 2026-2034. The growth trajectory is supported by the increasing prevalence of autism spectrum disorder, rising awareness among the general population, and expanding government-backed initiatives focused on early diagnosis and treatment access.

Autism spectrum disorder is a group of neurodevelopmental conditions characterized by impairments in social communication, restricted interests, and repetitive behaviors. The condition includes autistic disorder, Asperger's syndrome, and pervasive developmental disorder (PDD). The rising global diagnosis rate of ASD has significantly increased the demand for pharmacological therapies aimed at managing behavioral symptoms and associated comorbidities.

Market Dynamics

Market Drivers

One of the key drivers of the autism spectrum disorder therapeutics market is the growing number of government initiatives to increase awareness and early diagnosis of ASD. Governments across multiple regions are investing in public education programs, funding autism-focused foundations, and implementing inclusive healthcare policies. These initiatives promote early identification of symptoms, which directly increases the demand for therapeutic interventions.

For instance, in May 2025, Brazil's Ministry of Sports presented an autism-focused sports inclusion program at an international disability rights conference. Such programs highlight increasing institutional support for ASD patients, which positively influences treatment uptake and market growth.

Market Restraints

Despite growing awareness, the market faces restraints due to the widespread adoption of complementary and alternative therapies (CAM). Treatments such as chelation therapy, hyperbaric oxygen therapy, acupuncture, and dietary interventions are increasingly preferred by caregivers, limiting the adoption of conventional drug-based therapies. A publication by the American Academy of Pediatrics in March 2023 reported that nearly 95% of children with ASD had tried at least one alternative therapy.

Market Opportunities

The ASD therapeutics market presents significant opportunities due to the limited availability of FDA-approved drugs. Currently, only risperidone and aripiprazole are approved, and they primarily address irritability and aggression rather than core ASD symptoms. This unmet clinical need has encouraged pharmaceutical companies to focus on innovative therapies targeting social communication deficits and repetitive behaviors.

Market Challenges

The high cost of autism treatments remains a major challenge. Long-term therapy, specialist consultations, and branded medications impose a financial burden on families, especially in low- and middle-income countries. Even generic versions of approved drugs remain costly, restricting accessibility and slowing market penetration.

Autism Spectrum Disorder Therapeutics Market Trends

A major trend shaping the market is the expansion of the clinical pipeline and innovation in ASD therapeutics. Several companies are investing in novel drug mechanisms, including neuromodulation, enzyme replacement therapy, oxytocin-based treatments, and glutamatergic agents. The rising use of off-label drugs further underscores the urgent need for approved therapies targeting core ASD symptoms.

Segmentation Analysis

By Drug Type

By drug type, the market includes antipsychotics, SSRIs/antidepressants, stimulants, sleep medications, and others. The stimulants segment dominated the market in 2026, holding a 28.65% share, driven by their effectiveness in managing ADHD-related symptoms such as hyperactivity and inattention in ASD patients.

By Disease Type

Based on disease classification, autistic disorder accounted for the largest share, with 55.41% in 2026, due to its high prevalence and increasing government-supported intervention programs.

By Age Group

The pediatrics segment is expected to witness the fastest growth, supported by early diagnosis and increased parental awareness. The adult segment, however, accounted for 71.3% of total market share in 2026, reflecting continued therapeutic needs among adults.

By Distribution Channel

Hospital pharmacies dominated the market with a 39.57% share in 2026, owing to specialist prescriptions, insurance coverage, and controlled drug dispensing practices.

Regional Insights

North America dominated the global ASD therapeutics market in 2025, generating USD 1.28 billion in revenue and accounting for 58.1% market share. The dominance is attributed to high awareness levels, strong reimbursement frameworks, and increasing diagnosis rates. The U.S. market alone is projected to reach USD 1.26 billion by 2026.

Europe held the second-largest share, supported by improved screening programs and research initiatives. Meanwhile, Asia Pacific is expected to grow at the highest CAGR, driven by rising awareness, expanding healthcare infrastructure, and increasing research activities in countries such as Japan, China, and India.

Competitive Landscape

The autism spectrum disorder therapeutics market is highly fragmented due to the extensive use of off-label drugs. Key players include Otsuka Pharmaceutical, Johnson & Johnson Services, Pfizer, H. Lundbeck, Teva Pharmaceuticals, and AstraZeneca. These companies focus on expanding clinical pipelines, strengthening global distribution networks, and investing in research collaborations to gain a competitive edge.

Report Coverage

The Autism Spectrum Disorder Therapeutics Market report delivers a comprehensive and structured analysis of the global industry, focusing on both qualitative and quantitative insights. The coverage includes a detailed evaluation of market size and value for the base year 2025, estimates for 2026, and long-term projections up to 2034, along with the associated CAGR for the forecast period.

The report thoroughly examines market dynamics, including key drivers, restraints, opportunities, and challenges influencing market expansion. It provides in-depth insights into government initiatives, awareness programs, pricing challenges, and the impact of complementary and alternative therapies on the adoption of conventional ASD therapeutics.

A significant portion of the report is dedicated to segmentation analysis, covering the market by drug type, disease type, age group, and distribution channel. Each segment is analyzed with respect to market share, growth potential, and underlying demand factors. The study also highlights the dominance of specific segments such as stimulants, autistic disorder, adult patients, and hospital pharmacies based on reported data.

The report further presents a detailed regional outlook, analyzing performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Regional analysis includes market size, growth drivers, healthcare infrastructure, reimbursement scenarios, and country-level insights where applicable.

Additionally, the coverage includes a robust competitive landscape analysis, profiling key market players and evaluating their strategic initiatives such as research and development activities, clinical pipeline expansion, partnerships, and product development efforts. Recent key industry developments are also included to provide a complete understanding of the competitive environment.

Overall, the report serves as a strategic resource for stakeholders by offering actionable insights into current trends, future growth prospects, and structural dynamics of the autism spectrum disorder therapeutics market.

Conclusion

The global autism spectrum disorder therapeutics market demonstrates steady and sustained growth, supported by increasing diagnosis rates, rising awareness, and expanding government and institutional support across regions. With a market value of USD 2.21 billion in 2025, projected growth to USD 2.33 billion in 2026, and an expected reach of USD 4.06 billion by 2034, the market reflects strong long-term potential.

Limited availability of FDA-approved therapies has highlighted substantial unmet medical needs, encouraging pharmaceutical companies to intensify research and innovation efforts. At the same time, high treatment costs and the growing reliance on alternative therapies continue to pose challenges to market penetration, particularly in cost-sensitive regions.

Regionally, North America maintains a leading position due to advanced healthcare infrastructure and favorable reimbursement policies, while Asia Pacific emerges as a high-growth region driven by improving awareness and expanding research activities.

Overall, the market outlook remains positive, with innovation in drug development, supportive policy frameworks, and increasing global focus on autism care expected to shape the future trajectory of the autism spectrum disorder therapeutics industry through 2034.

Segmentation By Drug Type

  • Antipsychotic Drugs
  • SSRIs/Antidepressants
  • Stimulants
  • Sleep Medications
  • Others

By Disease

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

By Age Group

  • Pediatrics
  • Adults

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • U.S.
    • Canada
  • Europe (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East & Africa (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • GCC Countries
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Autism, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Regulatory Framework by Key Countries/Regions
  • 4.4. Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region
  • 4.5. Pipeline Analysis, By Key Players

5. Global Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Antipsychotic Drugs
    • 5.1.2. SSRIs/Antidepressants
    • 5.1.3. Stimulants
    • 5.1.4. Sleep Medications
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease
    • 5.2.1. Autistic Disorder
    • 5.2.2. Asperger Syndrome
    • 5.2.3. Pervasive Developmental Disorder (PDD)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Adults
    • 5.3.2. Pediatrics
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Antipsychotic Drugs
    • 6.1.2. SSRIs/Antidepressants
    • 6.1.3. Stimulants
    • 6.1.4. Sleep Medications
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease
    • 6.2.1. Autistic Disorder
    • 6.2.2. Asperger Syndrome
    • 6.2.3. Pervasive Developmental Disorder (PDD)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Adults
    • 6.3.2. Pediatrics
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Antipsychotic Drugs
    • 7.1.2. SSRIs/Antidepressants
    • 7.1.3. Stimulants
    • 7.1.4. Sleep Medications
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease
    • 7.2.1. Autistic Disorder
    • 7.2.2. Asperger Syndrome
    • 7.2.3. Pervasive Developmental Disorder (PDD)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Adults
    • 7.3.2. Pediatrics
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Antipsychotic Drugs
    • 8.1.2. SSRIs/Antidepressants
    • 8.1.3. Stimulants
    • 8.1.4. Sleep Medications
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease
    • 8.2.1. Autistic Disorder
    • 8.2.2. Asperger Syndrome
    • 8.2.3. Pervasive Developmental Disorder (PDD)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Adults
    • 8.3.2. Pediatrics
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Antipsychotic Drugs
    • 9.1.2. SSRIs/Antidepressants
    • 9.1.3. Stimulants
    • 9.1.4. Sleep Medications
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease
    • 9.2.1. Autistic Disorder
    • 9.2.2. Asperger Syndrome
    • 9.2.3. Pervasive Developmental Disorder (PDD)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Adults
    • 9.3.2. Pediatrics
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Type
    • 10.1.1. Antipsychotic Drugs
    • 10.1.2. SSRIs/Antidepressants
    • 10.1.3. Stimulants
    • 10.1.4. Sleep Medications
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease
    • 10.2.1. Autistic Disorder
    • 10.2.2. Asperger's Syndrome
    • 10.2.3. Pervasive Developmental Disorder (PDD)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Adults
    • 10.3.2. Pediatrics
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Curemark, LLC
    • 11.2.2. Yamo Pharmaceuticals
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Eli Lilly and Company
    • 11.2.5. AstraZeneca
    • 11.2.6. F. Hoffmann-La Roche Ltd
    • 11.2.7. Otsuka Holdings Co. Ltd.
    • 11.2.8. Johnson & Johnson Services, Inc.
    • 11.2.9. Teva Pharmaceutical Industries Ltd.
    • 11.2.10. H. Lundbeck A/S

List of Tables

  • Table 1: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 3: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 7: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 8: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 9: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 12: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 13: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 14: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 17: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 18: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 22: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 23: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 24: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 27: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 28: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Autism Spectrum Disorder Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 3: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 4: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 8: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 9: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 10: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 11: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 12: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 13: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 18: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 19: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 20: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 21: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 22: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 23: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 28: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 29: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 30: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 31: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 33: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 38: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 39: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 40: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 41: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 43: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 48: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 49: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 50: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 51: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 53: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Autism Spectrum Disorder Therapeutics Market Share (%), By Company, 2025